IMIC(SZ:000516) Zheng Quan Shi Bao Wang·2025-04-23 02:07Core Viewpoint - The company demonstrated strong operational resilience in a complex external environment, achieving steady revenue growth and significantly narrowing losses in its 2024 annual report [1] Financial Performance - The company reported a total revenue of 4.815 billion yuan, representing a year-on-year increase of 4.28% [1] - The net profit attributable to shareholders was -254 million yuan, a reduction in losses by 31.01% compared to the previous year, outperforming market expectations [1] Operational Efficiency - The company improved operational efficiency through continuous optimization, benefiting from its strategic focus on a "comprehensive medical + specialty" development model and "medical + health" service model [1] - The total number of outpatient and emergency services reached 2.5727 million visits, an increase of 7.70% year-on-year, while inpatient services grew by 10.73% to 205,700 visits [2] Service Capacity and Quality - The company’s various hospitals showed strong performance, with the Xi'an High-tech Hospital generating revenue of 1.525 billion yuan, up 2.68%, and a net profit of 84.76 million yuan, an increase of 21.63% [3] - The Central Hospital (including the North Campus) achieved revenue of 3.274 billion yuan, a 7.60% increase, while its net loss narrowed by 36.67% to -165 million yuan [3] Specialty Development - The company has developed a "comprehensive medical + specialty" innovative business model to meet diverse healthcare needs, establishing large specialty hospitals in various fields [4] - The company opened new specialty departments and expanded existing ones, enhancing its service capacity and optimizing its academic layout [5][6] Future Outlook - The company plans to leverage the opportunity of the tertiary hospital evaluation to drive quality development through institutional innovation, management reform, and technological updates [7] - With the release of new hospital capacities and the deepening of international strategies, the company is positioned to transition from traditional medical valuation to innovative medical valuation, warranting long-term attention [7]